FREE SHIPPING ON ORDERS OVER $200 Now testing for heavy metals and endotoxins ≥98.5% purity Third-party HPLC tested COA on every batch Fast, discreet US shipping
Ipamorelin 5mg research peptide vial
Growth & Longevity

Ipamorelin

Selective GH secretagogue

A selective ghrelin-receptor secretagogue studied in GH-release research.

From $65

In stock · ships in 1–2 business days

  • ✓ 99.845% purity (tested)
  • ✓ HPLC + mass-spec tested
  • ✓ View batch COA
  • ✓ Discreet US shipping
secretagogueGH research

Research Summary

Ipamorelin is a selective growth-hormone secretagogue studied in preclinical research for clean GH release with minimal effect on cortisol or prolactin pathways. For laboratory research use only.

Handling

Store the sealed lyophilized peptide at -20°C, protected from light and moisture. Let the vial reach room temperature before opening to limit condensation. Any further handling should follow your laboratory's own validated procedures, using appropriate protective equipment.

Research overview

Ipamorelin: what the research shows

Reviewed October 12, 2026 against PubMed and primary sources. For research context only, not medical advice.

What is ipamorelin?

Ipamorelin is a synthetic pentapeptide, Aib-His-D-2-Nal-D-Phe-Lys-NH2, developed at Novo Nordisk in the 1990s as a growth hormone secretagogue (GHS). It came out of a chemistry program built around the earlier growth hormone-releasing peptides (GHRPs), and was identified within a series of compounds that lack the central Ala-Trp dipeptide of GHRP-1 [1].

Its research interest comes from selectivity. When the original authors compared it with GHRP-6 and GHRP-2 in swine, ipamorelin released growth hormone (GH) without raising ACTH or cortisol above the levels seen after GHRH, while both GHRPs increased ACTH and cortisol. They described it as the first GHRP-receptor agonist with a selectivity for GH release similar to that of GHRH [1]. That profile makes ipamorelin a useful comparison compound when researchers want to separate GH-axis effects from adrenal-axis effects of ghrelin-receptor activation.

Ipamorelin contains two non-standard building blocks, 2-aminoisobutyric acid and a D-configured naphthylalanine, which PubChem's synonym list reflects [2].

Ipamorelin molecular identity
SequenceAib-His-D-2-Nal-D-Phe-Lys-NH2 (Aib = 2-aminoisobutyric acid; 2-Nal = 3-(2-naphthyl)alanine)
Length5 residues (pentapeptide amide)
Molecular formulaC38H49N9O5
Molecular weight711.9 g/mol
CAS number170851-70-4
PubChem CID9831659
Other namesNNC 26-0161, NNC-26-0161 (PubChem synonyms)

Mechanisms studied

The ghrelin receptor (GHS-R1a)

Synthetic GH secretagogues act through a G protein-coupled receptor that was cloned in 1996 from pituitary and hypothalamus and shown to be the target of this compound class [3]. Its endogenous ligand, ghrelin, a 28-amino-acid peptide with an octanoylated serine 3, was identified in rat stomach in 1999 [4]. The International Union of Pharmacology later designated GHS-R1a as the ghrelin receptor [5].

In the 1998 characterization, a pharmacological profiling with GHRP and GHRH antagonists indicated that ipamorelin, like GHRP-6, stimulates GH release through a GHRP-like receptor. In primary rat pituitary cells it released GH with a potency and efficacy similar to GHRP-6 [1].

Selectivity across pituitary hormones

In conscious swine, none of the secretagogues tested (ipamorelin, GHRP-6, GHRP-2) changed FSH, LH, prolactin, or TSH. The difference was in the adrenal axis: GHRP-6 and GHRP-2 raised ACTH and cortisol, whereas ipamorelin did not produce ACTH or cortisol levels significantly different from those after GHRH, even at exposures far above those needed for GH release [1].

Disposition in animal models

A 1998 rat pharmacokinetic comparison reported that ipamorelin had a systemic plasma clearance about five times lower than that of GHRP-6, was excreted mainly in urine (whereas GHRP-6 was predominantly excreted in bile), and was moderately resistant to metabolism [6].

Areas of research

Skeletal growth plate and bone models in rats

Novo Nordisk researchers studied ipamorelin in adult female rats over 15 days and measured longitudinal bone growth rate by tetracycline labelling in the proximal tibia. They reported that the growth rate increased compared with vehicle, while total IGF-I, IGF-binding proteins, and serum markers of bone formation and resorption did not change [7]. A 12-week study in young adult female rats compared ipamorelin, GHRP-6, and GH and found that all three increased bone mineral content measured by DXA. Additional measurements showed that this reflected larger bone dimensions rather than higher volumetric bone mineral density [8].

Glucocorticoid models

In an adult rat model of glucocorticoid exposure, a 2001 study reported that co-administration of ipamorelin counteracted the glucocorticoid-associated decrease in periosteal bone formation [9]. This places ipamorelin in research on how GH-axis signaling interacts with steroid-induced changes in bone.

Gastrointestinal motility models

Ghrelin-receptor activation also affects gut motility, which led to the study of ipamorelin in a rat model of postoperative ileus. In fasted rats subjected to laparotomy and intestinal manipulation, a single administration of ipamorelin or GHRP-6 shortened the time to the first bowel movement, and repeated administration increased cumulative fecal pellet output over 48 hours [10]. This is the line of research that later reached a clinical trial (see below).

Open research questions

  • Whether the selectivity seen in swine and rats holds across other species and with longer exposure.
  • How ipamorelin's lack of adrenal-axis activation relates to receptor signaling bias compared with GHRP-2 and GHRP-6.
  • The relevance of rat bone findings to animals with different growth-plate biology.

State of the human evidence

Ipamorelin has a small amount of published human data, all from controlled research settings:

  • Pharmacology. A 1999 pharmacokinetic and pharmacodynamic modeling study in healthy male volunteers described a short terminal half-life and a single episode of GH release followed by a return toward baseline [11].
  • Postoperative ileus. A 2014 phase 2, multicenter, randomized, double-blind, placebo-controlled proof-of-concept study in adults after bowel resection found no significant differences between ipamorelin and placebo in its key and secondary efficacy analyses [12].

No ipamorelin product has been approved. A 2026 narrative review of GH-axis peptides used outside medical supervision stressed the gap between this limited clinical evidence and unsupervised use, and the uncertainty around the composition of products in unregulated supply chains [13]. FDA has also referenced a published study reporting serious adverse events, including a death, when ipamorelin was given in a gastric-motility setting [14].

Regulatory status

  • Not FDA approved. A search of Drugs@FDA on October 12, 2026 returned no approved drug product containing ipamorelin [15].
  • Compounding. FDA's list of bulk drug substances that may present significant safety risks (content current as of April 22, 2026) places ipamorelin acetate in category 2 under the 503B interim policy, added September 29, 2023, and also lists it among nominations that were withdrawn. FDA cites a potential risk of immunogenicity, the added complexity of characterizing a peptide with unnatural amino acids, and a published report of serious adverse events [14].
  • Sport. The World Anti-Doping Agency 2026 Prohibited List names ipamorelin under S2.2.4, among growth hormone secretagogues and their mimetics, within class S2, which is prohibited at all times [16].

Status checked October 12, 2026. Rejuvatide supplies ipamorelin strictly as a research chemical for in vitro and laboratory use. It is not sold for human or veterinary use.

Testing and quality

Every Rejuvatide lot of ipamorelin is tested by an independent laboratory for purity by HPLC and identity by mass spectrometry, and is also tested for endotoxin. The current certificates are shown below and in our COA library, where you can match the lot number on your vial to its report. Certificates are published exactly as the laboratory issued them.

Ipamorelin is also a component of the CJC-1295 No DAC + Ipamorelin blend. For comparison work with the older, less selective secretagogues, see GHRP-2 and GHRP-6, or browse all growth-axis research peptides.

Storage of lyophilized material

Ipamorelin ships as a lyophilized (freeze-dried) powder, which is stable at ambient temperature during transit. For long-term storage, keep sealed vials at -20°C, protected from light and moisture. Allow a vial to reach room temperature before opening to limit condensation. Handling of any prepared solutions should follow your laboratory's own validated procedures.

Certificate of Analysis

Independently tested by Freedom Diagnostics. This is the certificate for the current batch of Ipamorelin.

99.845%HPLC purity
Lot 36319Tested batch

Your browser cannot display the PDF inline. Open the Certificate of Analysis.

Ipamorelin FAQ

What is ipamorelin?

Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that activates the ghrelin receptor, GHS-R1a. It was developed in the 1990s as a growth hormone secretagogue and is studied as a selective tool compound in GH-axis research.

Why is ipamorelin called selective?

In the original swine studies, ipamorelin released GH without raising ACTH or cortisol beyond the levels seen with GHRH, whereas GHRP-2 and GHRP-6 raised both. None of the compounds changed FSH, LH, prolactin, or TSH.

Is ipamorelin FDA approved?

No. It was studied in a phase 2 trial for postoperative ileus, which found no significant difference from placebo on its efficacy measures, and no ipamorelin product has been approved.

Is ipamorelin banned in sport?

Yes. The WADA 2026 Prohibited List names ipamorelin under S2.2.4 (growth hormone secretagogues), which is prohibited at all times.

What sizes does Rejuvatide offer?

Ipamorelin is available in 5mg and 10mg vials of lyophilized powder.

How is Rejuvatide ipamorelin tested?

Each lot is tested by an independent laboratory for HPLC purity, mass-spec identity, and endotoxin. The certificates are on the product page and in the COA library, matched to the lot number on the vial.

Is ipamorelin for human use?

No. Rejuvatide sells ipamorelin for laboratory research use only. It is not for human or veterinary use, and nothing on this site is medical advice.

References

  1. Raun K, Hansen BS, Johansen NL, et al. Eur J Endocrinol. 1998;139(5):552-61. PubMed 9849822
  2. PubChem. Ipamorelin, Compound CID 9831659. National Library of Medicine. Source
  3. Howard AD, Feighner SD, Cully DF, et al. Science. 1996;273(5277):974-7. PubMed 8688086
  4. Kojima M, Hosoda H, Date Y, et al. Nature. 1999;402(6762):656-60. PubMed 10604470
  5. Davenport AP, Bonner TI, Foord SM, et al. Pharmacol Rev. 2005;57(4):541-6. PubMed 16382107
  6. Johansen PB, Hansen KT, Andersen JV, et al. Xenobiotica. 1998;28(11):1083-92. PubMed 9879640
  7. Johansen PB, Nowak J, Skjaerbaek C, et al. Growth Horm IGF Res. 1999;9(2):106-13. PubMed 10373343
  8. Svensson J, Lall S, Dickson SL, et al. J Endocrinol. 2000;165(3):569-77. PubMed 10828840
  9. Andersen NB, Malmlöf K, Johansen PB, et al. Growth Horm IGF Res. 2001;11(5):266-72. PubMed 11735244
  10. Venkova K, Mann W, Nelson R, et al. J Pharmacol Exp Ther. 2009;329(3):1110-6. PubMed 19289567
  11. Gobburu JV, Agersø H, Jusko WJ, et al. Pharm Res. 1999;16(9):1412-6. PubMed 10496658
  12. Beck DE, Sweeney WB, McCarter MD. Int J Colorectal Dis. 2014;29(12):1527-34. PubMed 25331030
  13. Dominikowski A, Rękoś Z, Olejarz M, et al. Front Endocrinol (Lausanne). 2026;17:1822475. PubMed 42395176
  14. U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of April 22, 2026). Source
  15. U.S. Food and Drug Administration. Drugs@FDA: FDA-Approved Drugs (searched October 12, 2026). Source
  16. World Anti-Doping Agency. The 2026 Prohibited List, S2 Peptide Hormones, Growth Factors, Related Substances and Mimetics. Source